Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Lugtenburg · SciRah

Researcher profile · Semantic Scholar

P. Lugtenburg

Share profile

P. Lugtenburg — researcher profile on SciRah

h-index: 47
Works: 234
Citations: 9,337

Most-cited papers

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
C. Thieblemont, T. Phillips, H. Ghesquières, Che-Ah Y. Chan +19 more
2022Journal of Clinical Oncology468 citations Open access
Semantic Scholar
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
M. Hutchings, R. Mous, M. Clausen, P. Johnson +14 more
2021The Lancet261 citations Open access
Semantic Scholar
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial
C. Thieblemont, Y. Karimi, H. Ghesquières, Che-Ah Y. Chan +20 more
2024Leukemia151 citations Open access
Semantic Scholar
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study.
K. Linton, U. Vitolo, Wojciech Jurczak, P. Lugtenburg +24 more
2024The Lancet Haematology145 citations Open access
Semantic Scholar
Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index
N. Mikhaeel, M. Heymans, J. J. Eertink, H. D. de Vet +12 more
2022Journal of Clinical Oncology132 citations Open access
Semantic Scholar
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
M. Topp, T. van Meerten, R. Houot, M. Minnema +18 more
2021British Journal of Haematology131 citations Open access
Semantic Scholar
A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
F. Morschhauser, P. Feugier, I. Flinn, R. Gasiorowski +20 more
2020Blood109 citations Open access
Semantic Scholar
18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma
J. J. Eertink, T. van de Brug, S. Wiegers, G. Zwezerijnen +7 more
2021European Journal of Nuclear Medicine and Molecular Imaging101 citations Open access
Semantic Scholar
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial
L. Fornecker, J. Lazarovici, I. Aurer, R. Casasnovas +21 more
2022Journal of Clinical Oncology72 citations Open access
Semantic Scholar
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.
J. J. Eertink, C. Burggraaff, M. Heymans, U. Duhrsen +21 more
2021Blood Advances67 citations Open access
Semantic Scholar
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
Joshua D. Brody, J. Jørgensen, D. Belada, Régis Costello +15 more
2025Blood66 citations Open access
Semantic Scholar
Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma
J. J. Eertink, G. Zwezerijnen, M. Heymans, S. Pieplenbosch +17 more
2023Blood58 citations Open access
Semantic Scholar
Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features
J. J. Eertink, G. Zwezerijnen, M. Cysouw, S. Wiegers +7 more
2022European Journal of Nuclear Medicine and Molecular Imaging40 citations Open access
Semantic Scholar
How I treat older patients with DLBCL in the frontline setting
P. Lugtenburg, P. Mutsaers
2022Blood37 citations Open access
Semantic Scholar
An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients
M. C. Ferrández, S. Golla, J. J. Eertink, B. D. de Vries +29 more
2023Scientific Reports36 citations Open access
Semantic Scholar
Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor
G. Zwezerijnen, J. J. Eertink, M. C. Ferrández, S. Wiegers +6 more
2022European Journal of Nuclear Medicine and Molecular Imaging34 citations Open access
Semantic Scholar
Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?
J. J. Eertink, Elisabeth A. G. Pfaehler, S. Wiegers, T. van de Brug +5 more
2021Journal of Nuclear Medicine31 citations Open access
Semantic Scholar
Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.
Ruben Al de Groen, R. van Eijk, Stefan Böhringer, T. van Wezel +26 more
2021Blood Advances29 citations Open access
Semantic Scholar
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands
A. Spanjaart, E. Pennings, P. Mutsaers, S. van Dorp +17 more
2023Cancers26 citations Open access
Semantic Scholar
Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018
M. Durmaz, O. Visser, E. Posthuma, R. Brouwer +9 more
2022Blood Cancer Journal23 citations Open access
Semantic Scholar
Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands
E. Pennings, M. Durmaz, O. Visser, E. Posthuma +5 more
2024Blood Cancer Journal22 citations Open access
Semantic Scholar
18F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study
C. Burggraaff, J. J. Eertink, P. Lugtenburg, O. Hoekstra +9 more
2021Journal of Nuclear Medicine21 citations Open access
Semantic Scholar
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.
M. Chamuleau, F. Stenner, D. Chitu, U. Novak +27 more
2023The Lancet Haematology20 citations Open access
Semantic Scholar
Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989–2017
J. Driessen, O. Visser, J. Zijlstra, P. Lugtenburg +3 more
2020Leukemia20 citations Open access
Semantic Scholar
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
J. Driessen, M. Kersten, L. Visser, A. P. van den Berg +18 more
2022Leukemia19 citations Open access
Semantic Scholar
Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study.
M. Brink, X. Kahle, J. Vermaat, J. Zijlstra +13 more
2021Blood Advances19 citations Open access
Semantic Scholar
Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma
J. J. Eertink, G. Zwezerijnen, S. Wiegers, S. Pieplenbosch +15 more
2022Blood Advances17 citations Open access
Semantic Scholar
Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities
A. Spanjaart, E. Pennings, M. Kos, P. Mutsaers +12 more
2022JCO Oncology Practice16 citations Open access
Semantic Scholar
Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma
G. Zwezerijnen, J. J. Eertink, C. Burggraaff, S. Wiegers +8 more
2021Journal of Nuclear Medicine15 citations Open access
Semantic Scholar
Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1
J. Vose, T. Feldman, M. Chamuleau, W. Kim +16 more
2023Blood14 citations Open access
Semantic Scholar
Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.
M. Clausen, P. Lugtenburg, M. Hutchings, P. Johnson +9 more
202114 citations
Semantic Scholar
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma
L. Falchi, A. Sureda, S. Leppä, J. Vermaat +18 more
2025Blood13 citations Open access
Semantic Scholar
Validation of an Artificial Intelligence–Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma
M. C. Ferrández, S. Golla, J. J. Eertink, S. Wiegers +16 more
2024Journal of Nuclear Medicine13 citations Open access
Semantic Scholar
Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort
K. Linton, W. Jurczak, P. Lugtenburg, E. Gyan +19 more
2023Blood13 citations Open access
Semantic Scholar
Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018
M. Dinnessen, O. Visser, S. Tonino, E. Posthuma +4 more
2021Blood Cancer Journal13 citations Open access
Semantic Scholar
Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab.
T. Phillips, P. Lugtenburg, Anupama Kalsekar, A. Mutebi +7 more
2023Clinical Lymphoma, Myeloma & Leukemia12 citations Open access
Semantic Scholar
Measuring Total Metabolic Tumor Volume from 18F-FDG PET: A Reality Check
R. Boellaard, G. Zwezerijnen, Irène Buvat, Laurence Champion +16 more
2025Journal of Nuclear Medicine11 citations Open access
Semantic Scholar
Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2
Joshua D. Brody, J. Joergensen, D. Belada, Régis Costello +13 more
2023Blood11 citations Open access
Semantic Scholar
S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
A. Sureda, L. Falchi, S. Leppa, J. Vermaat +15 more
2023HemaSphere11 citations Open access
Semantic Scholar
Epcoritamab (epco) with gemcitabine + oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rate even in pts failing CAR T therapy.
J. Brody, B. Wahlin, T. Phillips, R. Costello +7 more
2022Journal of Clinical Oncology11 citations
Semantic Scholar
Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
Y. Karimi, C. Thieblemont, H. Ghesquières, Che-Ah Y. Chan +15 more
2024Journal of Clinical Oncology10 citations Open access
Semantic Scholar
Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial
L. Falchi, A. Sureda Balari, S. Leppä, J. Vermaat +16 more
2024Blood10 citations
Semantic Scholar
Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.
R. Merryman, D. Belada, A. Sureda, S. Leppä +15 more
2023Journal of Clinical Oncology10 citations Open access
Semantic Scholar
Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
L. Falchi, P. Abrisqueta, M. Nijland, S. Leppä +17 more
2022Blood10 citations Open access
Semantic Scholar
Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
T. Phillips, C. Thieblemont, H. Ghesquières, Che-Ah Y. Chan +19 more
2022Blood10 citations Open access
Semantic Scholar
Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma
Matias Mendeville, J. Janssen, G. T. L. Vries, E. van Dijk +21 more
2025Nature Communications9 citations Open access
Semantic Scholar
EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL.
J. Vose, U. Vitolo, P. Lugtenburg, M. Chamuleau +15 more
2024Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Cellular therapy in lymphoma
A. Sureda, P. Lugtenburg, M. Kersten, M. Subklewe +10 more
2023Hematological Oncology9 citations Open access
Semantic Scholar
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial
C. Casulo, A. Santoro, G. Cartron, K. Ando +16 more
2022Cancer Reports9 citations Open access
Semantic Scholar
A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands
D. Issa, A. Dinmohamed, M. Wondergem, H. Blommestein +5 more
2020Leukemia and Lymphoma9 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Zijlstra×18
Invite
J. Zijlstra — researcher profile on SciRah
M. Chamuleau×16
Invite
M. Chamuleau — researcher profile on SciRah
S. Wiegers×13
Invite
S. Wiegers — researcher profile on SciRah
J. J. Eertink×12
Invite
J. J. Eertink — researcher profile on SciRah

×12

Invite

H. D. de Vet — researcher profile on SciRah

R. Boellaard×12

Invite

R. Boellaard — researcher profile on SciRah

M. Hutchings×11

Invite

M. Hutchings — researcher profile on SciRah

Invite

K. Linton — researcher profile on SciRah

O. Hoekstra×10

Invite

O. Hoekstra — researcher profile on SciRah

Invite

M. Kersten — researcher profile on SciRah

Invite

M. Nijland — researcher profile on SciRah

C. Thieblemont×9

Invite

C. Thieblemont — researcher profile on SciRah